Investment follows evidence

In MedTech, the chicken-and-egg question is not whether funding or evidence comes first. It is recognising that evidence is what makes the funding possible.

In medical devices, founders spend an extraordinary amount of time chasing investment. Pitch decks are refined, financial models become increasingly sophisticated, and countless hours are spent trying to convince investors that a technology has the potential to change lives. Yet one truth remains remarkably consistent across our industry.

Capital follows confidence.

Not hope. Not enthusiasm. Not even a brilliant engineering solution.

Evidence.

It’s a lesson that many first-time founders learn the hard way. They view clinical studies as something that happens after funding arrives, as an expensive milestone to be tackled once the capital has been secured.

The reality is often the opposite.

Clinical evidence is what unlocks the investment in the first place.

The good news? That evidence doesn’t always require a 500-patient pivotal trial conducted across multiple continents with a fancy EDC. Some of the most exciting medical device companies have attracted strategic partners and investors on the back of relatively small, carefully designed feasibility or early clinical studies. Strategic investors rarely invest because a study is large. They invest because the study answers the right questions. The size of the study is rarely the story. The quality of the data is.

A thoughtfully designed early feasibility study that answers the right clinical questions, captures meaningful endpoints and demonstrates patient benefit can fundamentally change the trajectory of a company. It reduces uncertainty. It validates engineering assumptions. It demonstrates clinical adoption. Most importantly, it provides independent evidence that investors can believe.

Money likes data.

The investment community understands that innovation carries risk. Their job is to determine whether that risk is reducing over time. Every well-executed patient enrolled, every clinically meaningful endpoint achieved and every robust dataset generated moves that conversation in the right direction.

Large medical device companies are constantly scanning the market for technologies that complement their portfolios. They aren’t simply buying ideas, they’re buying confidence. Confidence that clinicians can use the device. Confidence that patients benefit. Confidence that regulators and future payers will respond positively.

Quality clinical evidence is often what earns a company a place on that shortlist.

This is why founders should reconsider another common assumption, that engaging an experienced CRO early is simply another cost on an already stretched budget.

It isn’t.

It is an investment in creating an evidence package that investors will actually value.

The decisions made before the first patient is enrolled have enormous downstream consequences. Selecting the right endpoints, choosing appropriate investigators, defining meaningful success criteria, ensuring data quality and anticipating regulatory expectations all influence how compelling the final story becomes.

Clinical studies don’t just generate data.

They generate credibility.

An experienced CRO should be helping founders think beyond operational delivery. The conversation should include questions such as: What evidence will our next funding round require? What questions will strategic partners ask? Which data points will support future regulatory submissions? How do we design today’s study so it continues creating value several years from now?

When viewed through that lens, clinical development becomes a commercial strategy rather than simply a regulatory exercise.

Jurisdiction selection deserves the same strategic thinking.

Too often, founders default to traditional markets without considering where they can generate the strongest evidence most efficiently. Australia and the broader Asia-Pacific region continue to offer a compelling environment for early-stage medical device studies, high-quality healthcare systems, internationally respected investigators, efficient study start-up and access to experienced clinical research teams.

Perhaps most importantly, the data generated is globally respected.

No investor has ever paused a funding discussion to ask, “Why did you treat patients in Australia?” or “Why was your early feasibility study conducted in Asia-Pacific?”

Quite the opposite.

Quality evidence is quality evidence.

What matters is that the study is well designed, ethically conducted, scientifically rigorous and produces credible results.

Founders should think of their first clinical study as more than a regulatory milestone. It is one of the company’s most valuable commercial assets. Long after the final patient has completed follow-up, that dataset will continue supporting investor presentations, partnership discussions, acquisition conversations and regulatory submissions.

The strongest companies recognise this early.

They don’t ask, “How cheaply can we run our first study?”

They ask, “How valuable can we make our first dataset?”

Because in medical technology, investment doesn’t create evidence.

Evidence creates investment.

About the Author

Jules Bligh is the Co-founder and Director of Operations at Ascend Clinical Research Organisation, an Asia Pacific-based specialist CRO supporting global medical device companies with offices across Australia, New Zealand & Singapore. With more than 20 years’ experience in clinical research, regulatory strategy and medical device development, Jules has led the delivery of hundreds of clinical trial sites from first-in-human feasibility studies through to pivotal and post-market research. Passionate about helping innovators generate meaningful clinical evidence, she is a strong advocate for pragmatic trial design, high-quality data and the strategic role clinical research plays in attracting investment and accelerating commercial success.